The companies expect to complete the submission of the NDA for treatment of MDD in the second half of 2022; associated filing for postpartum depression is anticipated in the first half of 2023
Funds will be allocated to accelerate rapid production and high-end curation of whole genome sequences for its clinical application
The USFDA approval in AS marks the fifth indication for Rinvoq in chronic immune-mediated diseases
Onshore manufacturing facility is expected to be based in Quebec and produce up to 100 million mRNA respiratory vaccine doses annually
CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
Pharma exports in 2021-22 sustain a positive growth despite global trade disruptions
The round also saw participation from US-based fund 57 Stars, a few prominent angel investors, existing investors Stellaris Venture Partners, Vertex Ventures, and Alteria Capital
The management believes that its strong product pipeline, diversified innovative product portfolio, continued expansion into new geographies and FGMP accreditations will help sustain the growth momentum in the coming few years
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
Nocria’s hand-held device uses gentle, controlled puffs of air in the ears for treating migraine attacks
Subscribe To Our Newsletter & Stay Updated
